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Background: The prevalence of obesity and related diseases has increased enormously in the 
last few decades, becoming a very important medical and social issue. Because of the increasing 
number of people who need weight loss therapies and the high costs associated with these, the 
search for reliable predictors of success for weight loss and weight maintenance treatments 
has become a priority.
Objective: A literature review was undertaken to identify possible predictors of outcome of 
weight loss and weight maintenance in patients treated with antiobesity drugs.
Results: For the majority of variables, published data are not sufficient to define their role on 
final outcomes. Among all considered factors, only early response to treatment appeared to be a 
reliable positive predictor, and diabetes a negative predictor of weight loss and maintenance.
Conclusion: To date, no definitive results have been obtained. Due to the great benefits of reli-
able predictors of outcome associated to currently available antiobesity drugs and those under 
development, identifying these predictors has to be supported and encouraged.
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Introduction
In the last decade, the prevalence of overweight and obesity (defined as BMI . 25 kg/m2 
and .30 kg/m2, respectively) and their complications (especially type 2 diabetes, 
cardiovascular diseases, obstructive sleep apnea, osteoarthritis, male and female 
infertility, and certain forms of cancer) has greatly increased among adults and children. 
It has become an alarming medical and social issue1 resulting from socioeconomic 
and behavioral changes in modern society (leading to increased energy consumption 
and decreased energy expenditure),2 and biological factors.3
Weight loss of 5%–10% of initial body weight reduces cardiovascular and metabolic 
health risks associated with obesity.4 International Health Guidelines4,5 recommend 
lifestyle modification as the first strategy in the management of obesity. If lifestyle 
modification alone is ineffective, pharmacotherapy may be considered for individuals 
with a BMI $ 30 kg/m2 or for those with a BMI $ 27 kg/m2 with comorbidities 
(eg, hypertension, diabetes, obstructive sleep apnea, type 2 diabetes) or a family 
history of overweight. Bariatric surgery should be reserved for individuals with a 
BMI $ 40 kg/m2 or $35 kg/m2 and comorbidities who do not lose weight with lifestyle 
modification and pharmacotherapy.4,5 Very recently, US Food and Drug Administration 
has approved the use of Allergan’s LAP-Band Adjustable Gastric Banding System for 
people with a BMI . 35 kg/m2 without comorbidities or for .30 kg/m2 and at least 
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Several studies have shown that the different antiobesity 
drugs, in conjunction with lifestyle treatments, can induce a 
weight loss up to 5%–10%, even if there is a great variability 
in individual response to a specific treatment.7–9 Several 
different treatments, based on lifestyle modifications,10–12 
drugs,13 and surgery14,15 have been developed in the past, and 
some others are currently being studied.13
The investigation for factors responsible for obesity 
onset and response to antiobesity treatments started in the 
early 1960s,16,17 and the number of studies in this field has 
multiplied over the years. Most studies showed a wide vari-
ability in inter-individual response to all kinds of treatments,18 
a usually modest result in weight loss and maintenance,19 and 
the involvement of many environmental, genetic, and behav-
ioral factors.19–23 However, predictors of outcome continue to 
be poorly understood. Availability of good predictors would 
allow physicians to match treatment to patients, and would 
improve cost-efficacy and patient’s chances of success in 
losing and maintaining weight.22,23
This article focuses on factors that have been suggested as 
possible predictors of weight loss and/or weight maintenance 
in patients treated with orlistat, diethylpropion, mazindol, 
sibutramine, and topiramate (Table 1).
Methods and study description
A literature search was performed using PubMed data-
base entering the drug name “and weight loss” for drugs 
approved by the FDA specifically for weight loss (orlistat, 
phentermine, and diethylpropion); drugs previously 
approved by the FDA that have been recently withdrawn 
from the market (sibutramine, mazindol, and rimonabant); 
and drugs approved by the FDA for other indications 
that exhibit weight loss promoting effects (topiramate, 
  bupropion, and zonisamide). We found articles focusing 
on predictors in patients treated only with diethylpropion, 
orlistat, sibutramine, mazindol, and topiramate. Some 
studies investigated treatment outcomes in patients treated 
with an association of phentermine and fenfluoramine 
but, because this compound is no longer available and no 
comparative data with each single drug exists, these articles 
have not been included. Additional relevant articles from   
reference lists were included.
Only articles focusing on adults were included. Absolute 
or relative weight loss was the only considered variable. 
Thirty-three studies investigating gender, anthropometric, 
demographic, psychological, behavioral, and hereditary 
characteristics, associated medical conditions and habits, 
Table 1 Main characteristics of antiobesity medications included in the study
Drugs approved by FDA specifically for weight loss
Drug Mechanism of action Typical dosing Adverse effects Effect on weight
Orlistata,d,9,33 Limits fats absorption;  
pancreatic lipase inhibitor
120 mg tid Abdominal pain,  
bloating, flatulence, oily stools, 
diarrhea, decreased absorption  
of fat soluble vitamins  
Liver injury (rare)
2.9 kg placebo subtracted  
weight loss at 1 year
Diethylpropiona,e,9 Appetite suppressant;  
sympathomimetic amine
Average 75 mg/d Dizziness, headache,  
insomnia, restless, increase  
in blood pressure, palpitations,  
tachycardia, gastrointestinal  
symptoms, rash
3.0 kg placebo-subtracted  
weight loss in studies  
ranging 6–52 weeks
Sibutramineb,9,33 Appetite suppressant;  
serotonin and norepinephrine  
reuptake inhibitor
10–15 mg/d Hypertension,  
tachycardia
4.2 kg placebo-subtracted  
weight loss at 1 year
Mazindolb,13 Appetite suppressant;  
norepinephrine inhibitor.  
inhibitor of gastric acids  
and insulin secretion
1–4 mg/d Restlessness, hypertension,  
nervousness
Average 3 kg placebo subtracted   
weight loss in 12 week studies
Topiramatec,33 weight loss mechanism  
unknown. Supposed  
monoamine-mediated appetite 
suppression; increase in fat  
metabolism and reduction  
in lipogenesis
90–200 mg/d Cognitive impairment,  
peripheral neuropathy
6.5% pooled random-effects  
of topiramate on weight loss  
compared with placebo
Notes: aDrugs approved by FDA specifically for weight loss; bDrugs previously approved by FDA specifically for weight loss and recently withdrawn from the market; cDrugs 
approved by the FDA for the other indications that exhibit weight loss promoting effects; dDrug approved by FDA for long-term treatment; eDrug approved by FDA for 
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dietetic advices, and environmental factors were identified 
and included in this review.
All studies included subjects with a $25 kg/m2 of both 
genders, except for two24,25 including females only. Age 
ranged from 16 to 70 years. The number of patients included 
in the different studies ranged from 36 to 3277. The duration 
of the study varied from 8 to 208 weeks. Some included a 
run-in phase.26–31 The main characteristics of the patient 
sample and program of the considered studies are displayed 
in Table 2.
Predictors associated with orlistat 
treatments
Orlistat is a semisynthetic derivative of lipstatin which 
irreversibly and selectively binds to pancreatic lipases, 
  reducing fat absorption by approximately 30% (Table 3).32 
The prescribed dose is 120 mg, three times/day with 
meals. A meta-analysis33 including approximately 10,000 
participants treated for at least 1 year, reported a mean 
placebo-subtracted weight loss of 2.9 kg. Abdominal pain, 
bloating, flatulence, oily stools, and diarrhea represent 
common adverse effects; severe liver injury is rare.34
Demographic variables
Only one study35 investigated the impact of gender on weight 
loss, and found no significant difference in the percentage of 
initial body weight lost by males and females.
Psychological factors and eating behaviors
Orlistat weight loss was positively related to the traits ‘order’ 
(P , 0.05), ‘deliberation’ (P , 0.01), and ‘self-discipline’, 
included in the main personality factor conscientiousness35 
(which reflect the ability to have and to persist with a 
goal-directed and motivated behavior, hence to consider 
matters before acting, to be methodical, well organized, and 
self-disciplined). This suggests that people with a stronger 
personality and great conscientiousness can achieve higher 
levels of long-term compliance towards a high demanding 
treatment like orlistat, a characterized thrice-daily regimen, 
and dietary fat restriction. The importance of determination 
on treatment’s results is evident in European prescribing 
information36 that, based on several observations,26 orlistat 
is only recommended to those patients who have previously 
lost at least 2.5 kg by diet alone in a 4-week period, as 
an indication of their capacity to comply with prescribed 
dietary changes. Conversely, levels of restrained eating, 
anxiety, and depression showed no impact on the final 
outcome.35
Diabetes
Two studies30,37 pointed out the difficulty in losing weight 
experienced by diabetic patients treated with orlistat.
initial weight loss
A study conducted on 229 patients who completed a 2-year 
treatment26 showed that people who lost $5% of their   initial 
weight in the first 12 weeks achieved better final results 
than people who did not (−11.9 ± 0.8% vs −4.7 ± 0.5%; 
P = 0.0001). This finding was confirmed by another study38 
in which .80% of patients who achieved $5% reduction 
in their body weight after 3 and 6 months maintained .5% 
weight loss and .50% achieved $10% weight loss after 
12 months (P , 0.01). Accordingly, European36 and National 
Institute for Clinical Excellence39 prescribing guidelines, 
which recommend that only people who lose $5% of initial 
body weight after 12 weeks and $10% after 6 months should 
continue taking orlistat.
Associated dietetic and environmental 
factors
Pharmacist’s support was shown to improve patient’s 
  persistence with orlistat therapy but it did not improve the 
total amount of weight loss.40 The total daily calories assumed 
with diet (500 vs 1000 kcal/day)38 did not have a marked 
impact on the overall clinical outcome of weight reduction 
(average weight loss 11.8 and 11.4 kg respectively), while 
a low fat, but also carbohydrate, consumption was essential 
to lose weight.31
Predictors associated  
with diethylproprion treatments
Diethylpropion is an amphetamine like analog currently 
approved by FDA for short-term weight loss.9 A meta-
analysis conducted on several studies in which patients were 
treated with diethylpropion 75 mg/day in combination with 
lifestyle treatment showed an average 3.0 kg of additional 
weight loss, compared with placebo.9 Common side effects 
include central nervous system stimulation, dizziness, 
headache, insomnia, restlessness, mild increases in blood 
pressure, palpitations, mild tachycardia, mild gastrointestinal 
symptoms, and rash.9
To our knowledge, only one study41 focused on predictors 
of weight loss in patients treated with diethylpropion, showing 
no statistically significant effect of patients’ personality on 
weight loss, but just a positive correlation between social 
conformity and treatment completion (P , 0.004).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Main characteristics of the patient sample and program of the considered studies
Author, year Sample Type of study Program
Alberici et al77 BL: 51 p.  
eT: 49 p.  
BLCPCS: mA 44.1 ± 11.5. F 36.  
mBMi 24.0 ± 3.4.
Prospective study Treatment: Topiramate was administered following 
slow up titration; full dosage of 100 mg/day, bid 
regimen, reached within 4 weeks. 4 months treatment
Ben- 
Menachem et al75
BL: 49 p. F 28. mA 36.2 ± 11.7. mBw  
77.8 ± 16.8. mBMi 26.9 ± 5.9.  
eT: 38 p. F 22. mA 35.9 ± 11.5.  
mBw 75.8 ± 14.8. mBMi 26.3 ± 9.3.
Prospective study Treatment: 1 year. Topiramate added to pre-existing 
anticonvulsant therapy. Starting dose 25 mg/day, 
increased biweekly in 25 or 50 mg increments to the 
best-tolerated dosage providing maximum seizure 
control mean dosage after 3 months 81 mg/day 
(21–154 mg/day)
elfhag et al27 BL: 36 p.  
eT: 30 p.  
BLCPCS: F 22. mA 43 ± 12 (20–64).  
mBMi 40 ± 4 (33–45).
Prospective study Run in phase: 6 weeks. Clinical trial evaluating 
the effect of sibutramine on food consumption in 
laboratory test meals. 2 weeks each of: sibutramine, 
placebo, and a wash out period (crossover design) 
Treatment: 26 weeks. Sibutramine  
(15 mg/day) + monthly dietary advice
elfhag and  
Rossner19
BL: 36 p.  
F 27. mA 43 ± 12 years (20–64).  
mBMi 39 ± 4 (30–45).  
eT: 31 p.
Prospective study Run in phase: 6 weeks. Sibutramine/placebo and 
wash out period Treatment: 26 weeks. 15 mg/day 
sibutramine and dietary advice in monthly group 
sessions with a dietitian
elfhag et al35 BLCPCS: 478 p.  
F 301. mA 42.4 ± 12.2 (16–70).  
mBMi 42.4 ± 12.2 (26–68).
Retrospective analysis of  
patients who completed  
the study
1.   weight watcher treatment  
(control) or 
2. Sibutramine or  
3. Orlistat
Fabricatore et al45 BL: 224 P.  
F 180. mA 43.8 ± 10.2.  
C 146. Oe 76.  
Sibutramine: 55 p.  
Lifestyle modification: 55 p.  
Combined therapy: 60 p.  
Sibutramine + brief behavioral  
therapy: 54 p.  
eT: 185 p.
Prospective study 52 weeks treatment:  
1200–1500 kcal/day diet (15% proteins, 30% fats, 55% 
carbohydrates) + walking + random assignment to:  
a.   Sibutramine: 8 visits of 10–15 minutes with a 
primary care provider + pamphlet providing tips 
for healthy lifestyle + sibutramine 15 mg/day 
b.   Lifestyle modifications: 30 group behavior 
modification sessions 
c. Combined therapy (a + b) 
d.   Sibutramine + brief therapy: sibutramine  
15 mg/day + 8 sessions of 10–15 minutes behavior 
therapy sessions
Finer et al29 BL: 928 p.  
Nondiabetic: 771 p.  
F 611. C 763.  
mA 42.4 ± 10.7.  
mBw 97.5 ± 15.2.  
mBMi 35.0 ± 4.1.  
Diabetic: 157 p.  
mA 51.4 ± 9.6.  
F 84. C 153.  
mBw 101.3 ± 17.7.  
mBMi 35.7 ± 5.4.
Retrospective analysis of 
patients included in  
7 different studies
Run in phase: placebo run-in phase (3 studies);  
open-label sibutramine run-in phase (2 studies);  
very low calorie diet (1 study)  
Treatment: 52 weeks; random assignment to 
sibutramine (10 mg/day) or placebo (6 studies with 
fixed dose; 1 study with dose titrated depending on 
patient’s weight maintenance)
Frey et al50 BLCPCS: 110 p.  
C. F 74. A 42–48.  
BMi 35.3–35.4.  
Sibutramine group:  
54 p. F 38. mA 46.8 ± 10.5.  
mBw 99.2 ± 14.1.  
mBMi 35.1 ± 4.2.  
Placebo group: 56 p.  
F 36. mA 49.3 ± 11.0.  
mBw 104.5 ± 15.2.  
mBMi 35.5 ± 3.3.
Retrospective study on a  
part of patients who had  
completed the program
54 weeks treatment: random assignment to  
15 mg/day of sibutramine or placebo +  
behavior program (16 group sessions) +  
physical activity + diet (daily energy  
requirement minus 500 to 1000 kcal/day)
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Table 2 (Continued)
Author, year Sample Type of study Program
Greenway78 SiBUTRAMiNe: 83 obese  
patients with diabetes;  
2004 obese patients  
without diabetes.  
ORLiSTAT: 321 obese  
patients with diabetes; 2404 obese  
patients without diabetes.  
MAZiNDOL: 40 obese  
patients with diabetes;  
998 obese patients  
without diabetes.
Retrospective comparative 
analysis between a study 
focusing on diabetic  
patients and an average  
of studies in nondiabetic 
patients for each  
type of drug
12 weeks sibutramine treatment or  
52 weeks orlistat treatment or  
12 weeks mazindol treatment
Grudell et a47 BL: 181 p.  
Placebo: 62 p. F 54.  
mA 41.3 ± 1.4.  
mBw 95.9 ± 2.1.  
mBMi 34.5 ± 0.6.  
Sibutramine 10 mg:  
58 p. F 53. mA 42.2 ± 1.4.  
mBMi 34.8 ± 0.7.  
Sibutramine 15 mg:  
61 p. F 54.  
mA 44.8 ± 1.3.  
mBMi 33.9 ± 0.6. eT: 158 p.
Prospective study 12 weeks treatment: behavioral therapy (LeARN 
manual + 1 group session of 15 minutes each week 
led by a psychologist) + placebo or sibutramine 
10 mg/day or 15 mg/day
Hainer et al24 BL: 80 p.  
F. mA 43.9 ± 10.6 (18–65).  
mBMi 36.7 ± 4.8 (30–45).  
1st phase: sibutramine 38 p.  
Placebo 42 p. 2nd phase: 80 p.  
eT: 67 p.
Prospective study 1st phase: 4 months; random assignment to 
sibutramine 10 mg/day or placebo  
2nd phase: 8 months; sibutramine + 5–6 MJ/day 
diet (50%–60% carbohydrates; 15%–20% proteins; 
25%–30% fat) + physical activity + food diary records
Hansen et al46 BL: 605 p.  
BMi 30–45; 18–65 yr  
Completers of the  
1st phase: 505 p.  
mA 40.4 ± 10.4.  
mBw 102.5 ± 15.3.  
mBMi 36.7 ± 4.1.  
enrolled in the  
2nd phase: 467 p.  
352 sibutramine.  
115 placebo. eT: 263 p.
Prospective study 1st phase: 6 months; sibutramine (10 mg/day) and 
LCD (patient’s estimated daily energy expenditure 
minus 600 kcal/day. 45%–50% carbohydrates;  
30% fats; 15%–20% proteins)  
2nd phase: 18 months; random assignment for 
patients who achieved $5% of weight loss to 
sibutramine 10 mg/day (352 p) or placebo (115 p)
Hauner et al53 BL: 348 p. BMi 30–40; 18–65 yr.  
Sibutramine: 174 p.  
F 136. mA 44.5 ± 1.2. mBw  
100.2 ± 1.9. mBMi 35.6 ± 0.6.  
Placebo: 174 p. F 123.  
mA 47.3 ± 1.3. mBw  
105.4 ± 2.0. mBMi 35.7 ± 0.5.
Retrospective analysis  
of patients included  
in the study
54 weeks treatment: 20 group sessions and 
prescription of a diet (500/1000 kcal minus  
of the daily required energy expenditure) +  
physical activity + sibutramine or placebo  
(random assignment)  
2 years follow up
Hsiao et al54 BL: 131 p. Sibutramine:  
87 p. Placebo 44 p.  
eT: 118 p.  
BLCPCS:  
Sibutramine 82 p. F 41.  
mA 31.7 ± 4.9.  
mBw Placebo 37 p. F 17.  
mA 31.1 ± 5.8.  
mBw 83.8 ± 15.0.  
mBMi 29.8 ± 3.4.
Prospective study 12 weeks treatment:  
sibutramine 10 mg/day or placebo
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Table 2 (Continued)
Author, year Sample Type of study Program
Hsiao et al57 BL: 131 p.  
Sibutramine: 87 p.  
Placebo 44 p.  
eT: 118 p.  
BLCPCS: Sibutramine 82 p. F 41.  
mA 31.7 ± 4.9.  
mBw Placebo 37 p. F 17.  
mA 31.1 ± 5.8.  
mBw 83.8 ± 15.0.  
mBMi 29.8 ± 3.4.
Prospective study 12 weeks treatment:  
sibutramine 10 mg/day or placebo
Klein et al76 BL: 26 p.  
eT: 22 p. F 13. BLCPCS: mA 41.5.  
mBMi 28.0 ± 6.6.  
mBw 80.3 ± 19.3.
Prospective study 6 months treatment: topiramate
LLoret- 
Linares et al37
BL:  
Sibutramine (3 studies):  
115–467 p. F 76%–84%.  
mA 40.4–43.3. mBMi 32.4–37.9.  
Orlistat (12 studies):  
422–3277 p. F 55%–87%.  
mA 40–53. mBMi 34.7–37.4.  
Rimonabant (4 studies):  
688–1826 p.
Retrospective comparative 
analysis between studies 
considering nondiabetic  
and diabetic subjects  
for each type of drug
Sibutramine: 10 or 20 mg once a day for  
52 or 104 weeks or  
Orlistat: 120 mg three times a day for  
52/76/104/208 weeks or  
Rimonabant: 20 mg daily for 52 or 104 weeks. All 
trials combined pharmacological therapy with a 
reduced-calorie diet
Malone and  
Alger-Maye40
BL: 30 p. F 26.  
mA 43.8 ± 9.7.  
mBw 127 ± 34.  
mBMi 45.5 ± 11.8.  
intervention group: 15 p.  
F 14. mA 44.9 ± 10.5.  
Bw 130 ± 39. BMi 48.3 ± 14.6.  
Control group:  
F 12. mA 42.8 ± 9.  
Bw 124 ± 30. BMi 42.8 ± 8.1.  
eT: 9 p. intervention group:  
7 p. Control: 2 p.
Prospective study Patients randomly assigned to the group followed by 
a community pharmacist (trained and educated for 
1 day to support clients during weight loss treatment 
with orlistat) or to the group not followed by a 
pharmacist and followed for 26 weeks
Norris et al30 BL: 31 studies.  
mA 48–66. F 50%.  
Fluoxetine (6 studies):  
296 p (total number).  
Orlistat (8 studies):  
2036 p (total number).  
Sibutramine (8 studies):  
1047 p (total number).  
Cimetidine 1 study.  
Diethylpropion (3 studies):  
40–58 p (single study).  
Mazindol (3 studies);  
10–64 p (single study).  
Phentermine (2 studies).
Meta-analysis of studies 
considering nondiabetic  
and diabetic subjects  
for each type of drug
Run-in period: 1–5 weeks in most studies; 
placebo + dietary counseling  
Treatment: Fluoxetine: 8 to 52 weeks or 
Orlistat: 12 to 57 weeks or 
Sibutramine: 12 to 52 weeks or 
Cimetidine: 12 weeks 
Dyethylpropion: 8 to 40 weeks or 
Mazindol: 6 to 12 weeks or 
Phentermine: 16 to 26 weeks
Peters et al25 BL: 149 p. F. mA  
54 ± 5.78 (45–65).  
mBw 103.41 ± 20.65  
(68.03–175.54).  
mBMi 40.10 ± 8.01 (30–76).  
FU: 74 p.
Prospective study 6 months treatment: sibutramine  
15 mg/day + 1 hour/month behavior modification 
seminar + daily exercise
Rissanen et al26 BLCPCS: 220 p.  
F 178. A 42–49.  
Bw 90.3–101.9.  
BMi 32.7–36.1.
Retrospective analysis of 
patients who completed  
the treatment in two  
different studies
Run in phase: 4 weeks; hypocaloric diet (30% fat; 
500 kcal/day energy deficit) + placebo  
Treatment: 2 years; random assignment to:  
120 mg/day orlistat or placebo + diet
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Table 2 (Continued)
Author, year Sample Type of study Program
Risser et al63 BL:  
PAR1: 22 p.  
F 90.9%.  
mA 4 9.9 ± 12.  
mBMi 39.3 ± 7.  
Non-PAR: 47 p.  
F 78.7%. mA 47.1 ± 10.  
mBMi 37.1 ± 6.12.
Retrospective analysis 1st phase: 8 weeks; 800–1220 kcal/day diet +  
24-hour food diary + visits (first 10 weeks:  
2–5 days/week) + sibutramine 15 g/daily  
(flexible doses adjusted depending on patient)  
2nd phase: 40 weeks; weight maintenance 
through well-balanced meals and regular 
exercise + sibutramine 15 mg/day  
(flexible doses adjusted depending  
on patient)
Rodin et al41 BL: 204 p.  
Clinic 1: 144 p.  
F 129. A 18–59.  
Bw 28%–199% overweight.  
Clinic 2: 60 p. F 60. A 18–54.  
Bw 17%–183% overweight.  
eT: clinic 1: 33 p.  
Clinic 2: 56 p.
Prospective study Clinic 1: 14 weeks (8 weeks treatment): random 
assignment to 4 groups: behavior modification 
treatment, diethylpropion 65 mg/day,  
mazindol 2 mg/day, placebo  
Clinic 2: 10 weeks; (9 weeks treatment): behavior 
therapy for all patients + random assignment to two 
different formulations of mazindol or placebo
Shimizu and Mori66 
Shimizu et al67
 BL: 24 p. Trp64Trp:  
16 p. Trp64Arg: 8 p.  
BMi . 35 kg/m2.  
BL: 41 p. F 25. BMi . 35.
Prospective study 12 weeks treatment: mazindol (starting dose  
0.5 mg/day. increments of 0.5 mg/day every  
2 weeks up to 1.5 mg/day at week 6 and  
then continued until week 12)
Tankova et al59 BL: 173 p.  
Diabetic patients: 83 p.  
Sibutramine group:  
44 p. F 27. mA 45.2 ± 5.2.  
mBMi 33.6 ± 2.2.  
Control group: 39 p.  
F 24. mA 44.8 ± 6.1.  
mBMi 33.9 ± 2.8.  
Nondiabetic patient: 90 p.  
Sibutramine group: 49 p.  
F 32. mA 41.9 ± 5.7.  
mBMi 34.3 ± 2.6.  
Control group: 41 p.  
F 27. mA 44.6 ± 6.0.  
mBMi 33.9 ± 2.2.
Prospective study 3 months treatment: hypocaloric diet (600 kcal/
day deficit on the estimated total daily energy 
expenditure. ,30% fat, 15% protein, 55%–60% 
carbohydrates) +30 minutes walking/day + random 
assignment to sibutramine once daily or placebo.  
First month dosage of sibutramine was 10 mg/day 
replaced by 15 mg/day in case of no change  
in body weight
Toplak et al38 BL: 430 p.  
BMi 30–43; 18–70 yr;  
Bw $90, waist circumference  
$88 cm (F) or $102 cm (M).  
Orlistat + 500 kcal/day diet: 215  
p. F 168. mA 41.3 ± 11.0. mBw  
103.4 ± 11.2. mBMi 37.3 ± 3.4.  
Orlistat + 1000 kcal/day diet:  
215 p. F 166. mA 41.1 ± 12.1.  
mBw 104.7 ± 12.8.  
mBMi 37.4 ± 3.6.  
eT: 264 p.
Prospective study 1 year treatment: orlistat 120 mg 3 times/
day + dietary counseling + daily food diary + random 
assignment to a diet (50% carbohydrates, 30% fat, 
20% protein) of 500 or 1000 kcal/day deficit  
Patients who achieved a 5% weight loss at both 
months 3 and 6 (295 p) were allowed to continue 
the study until month 12
Theisen et al74 BL: 26 p. F 10. mA  
37.4 ± 10.3 (20.7–65.3).  
M mBMi 28.1 ± 6.4.  
F mBMi 22.5 ± 3.5.  
eT: 18 p.
Prospective study 25 weeks treatment with topiramate 
added to existing anticonvulsant therapy 
(carbamazepine 12 p; carmanazepine + valproate 
3 p; carbamazepine + lamotrigine 3 p; 
carbamazepine + valproate + lamotrigine 3 p; 
carbamazepine + valproate + phenobarbital 1 p;  
carbamazepine + phenobarbital 1 p;  
carbamazepine + phenytoin 1 p;  
phenytoin + phenobarbital 1 p;  
phenytoin + lamotrigine + phenobarbital 1 p)
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Table 2 (Continued)
Author, year Sample Type of study Program
Ullrich et al31 BL: 261 p. F 214.  
mA 41.4 ± 9.8.  
mBMi 36.8 ± 4.2.  
Sibutramine group: 204 p.  
F 168. mA 41.4 ± 9.7.  
mBMi 36.6 ± 4.2.  
Placebo group: 57 p.  
F 46. mA 41.3 ± 10.0.  
mBMi 37.1 ± 3.8.
Retrospective analysis of 
people who completed the 
study
Run in phase: 4 weeks; hypocaloric diet (600 kcal/
day deficit on patient’s estimated basal metabolic 
rate. #30% fat; protein and carbohydrate ad 
libitum) + placebo (3 times/day with meals) 
Treatment: 72 weeks; orlistat (120 mg × 3/day). 
4-day food diary at weeks −4, −2, 0, 12, 24, 36, 48, 
64. Group weight management program sessions 
(one each 4 weeks)
van Baak et al48 BL: 605 p. BMi 30–45; 17–65 yr.  
After 6 mo run in phase: 467 p.  
eT: 261 p. F 214. mA 41.4 ± 9.8.  
BMi 36.8 ± 4.2.
Prospective study 1st phase: 6 months; sibutramine (10 mg/day) and 
LCD (patient’s estimated daily energy expenditure 
minus 600 kcal/day. 45%–50% carbohydrates; 30% 
fats; 15%–20% proteins)  
2nd phase: 18 months; random assignment for 
patients who achieved $5% of weight loss to 
sibutramine 10 mg/day (352 p) or placebo (115 p). 
Dietary advice and one meeting with a  
dietician a month
vazquez  
Roque et al44
BL: 48 p. Sibutramine 25 p.  
Placebo 23 p.  
Overweight: 24 p.  
mA 36.7 ± 1.7. F 17. C 87.5%.  
mBw 79.6 ± 1.6.  
mBMi 27.9 ± 0.3.  
Obese: 24 p. mA  
44.2 ± 2.6. F 13.  
C 95.8%. mBw 98.2 ± 2.7.  
mBMi 34.8 ± 0.7.  
eT: 43 p. Sibutramine 22 p.  
Placebo 21 p.
Prospective study 12 weeks treatment: LeARN manual (self-help 
behavioral manual for weight loss) + 10–15 minutes 
behavior therapy sessions (one every  
4 weeks) + random assignment to sibutramine 
15 mg/day or placebo
womble et al65 BL: Group 1: 59 p. F 31.  
M: mA 50.21 ± 7.39;  
mBMi 39.94 ± 5.99.  
F: mA 45.72 ± 9.2.  
mBMi 40.34 ± 8.20.  
Group 2: 32 p taken  
from group 1. F 15.  
eT group 1: 59 p.  
Group 2: 32 p.
Prospective study 6 months treatment for group 1; 12 months 
treatment for group 2  
For both groups, random assignment to:  
a.   Fenfluramine + mazindol (6 months;  
29 p. 12 months; 18 p) or 
b.   Fenfluramine + phentermine (6 months;  
25 p. 12 months; 11 p) or 
c.   Caffeine + ephedrine (6 months; 2 p. 12 months, 1 p) or 
d. Mazindol (6 months, 3 p. 12 months, 2 p)
Notes: 1Cases: patients who had received a prescription for sibutramine in response to priori authorization through their health care insurer (PAR). Controls: subjects 
who did not receive reimbursement, although they were prescribed, sibutramine (non-PAR).
Abbreviations: BL, sample characteristics at base line; BMi, body mass index (kg/m2); BLCPCS, baseline characteristics of people who completed the study; Bw, body 
weight; C, Caucasians; F, number of female patients; eT, sample characteristics at the end of the program; mA, mean age; mBMi, mean body mass index (kg/m2); mBw, mean 
body weight; Oe, other ethnicity; p, number of patients; yr, years old; LCD, low-calorie diet.
Predictors associated with 
sibutramine treatments
Sibutramine is a centrally-acting drug that reduces energy 
intake and increases satiety mainly through the inhibition of 
serotonine and norepinephrine reuptake (Table 4).8 Weight 
loss is enhanced by the stimulation of thermogenesis42,43 and 
the delay in gastric emptying.44 The prescribing dose was 
10–15 mg once daily. A recent meta-analysis33 that included 
2,838 participants treated with sibutramine for at least 1 year, 
showed a mean placebo-subtracted weight loss of 4.2 kg. 
The drug was withdrawn from the market in October 2010 
because of cardiovascular side effects.13
Psychological factors and eating behaviors
A study in 200327 demonstrated that patients with more 
  deviating levels (elevated or lowered from the mean) 
of physical demand states (inborn and natural primary 
drives, including hunger) and dependency orientation 
(which implies preoccupation with oral activity such as 
eating and   dependency on food, and which is typical of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Predictors of weight loss and maintenance in patients treated with orlistat
Author, year Predictors
Demographic and anthropometric factors elfhag et al35 PPwL: male gender
Psychological factors and eating behaviors elfhag et al35 PPwL: high levels of order and deliberation 
(conscientiousness). High levels of self-discipline 
and conscientiousness ntPwL: high levels of eating 
restraint, neuroticism, anxiety, and depression
initial weight loss in the lead-in period  
and under treatment
Rissanen et al26 PPwL: weight loss $2.5 kg during 4 weeks lead-in 
period; weight loss $5% body weight after 12 weeks 
treatment; $10% body weight after 6 months
Toplak et al38 PPwL: $5% weight loss at 3 and 6 months
Associated medical, dietetic,  
and environmental factors
Malone and Alger-Mayer40
Toplak et al38
Ullrich et al31
ntPwL: pharmacist’s support
ntPwL: 500 kc/day diet vs 1000 kcal/day diet
PPwL: low fat and carbohydrate intake
Abbreviations: NPwL, negative predictor of weight loss; NPwM, negative predictor of weight maintenance; ntPwL, not predictor of weight loss; ntPwM, not predictor 
of weight maintenance; PPwL, positive predictor of weight loss; PPwM, positive predictor of weight maintenance.
people vulnerable to social isolation) lost more weight 
when treated with sibutramine (r = 0.533, P = 0.002 and 
r = 0.478, P = 0.008, respectively). Initial signs of dif-
ficulties concerning physical demand states were strong 
positive predictors of weight loss (r = 0.533, P = 0.002), 
explaining 27% alone. These findings suggest that the drug 
could improve conscious control over instinctual drives; 
alternatively, it could increase the sensitivity to alterations 
in hunger and satiety, helping people with initial high 
levels of hunger urges to improve control on food intake. 
The enhanced satiety effect of sibutramine could also 
have helped patients with high oral dependency to give 
less importance to food and the support provided by being 
enrolled in a treatment program could have helped them 
to abstain from food.
In the same study,27 self-inspect ability (which means an 
ability to monitor and reflect on one’s behavior and thinking) 
was related to weight loss but was not a predictor.
Several studies24,28,35 have found that patients with more 
unrestrained eating (less cognitive control and conscious 
determination to resist eating, less strategic dieting) achieved 
greater weight loss, suggesting a negative influence of a 
pre-trial weight suppression on the subsequent treatment 
with sibutramine.24 At the same time, the increase in dietary 
restraint and the decrease in disinhibition score during 
weight reduction phase guaranteed the success of weight 
loss maintenance.24
Discordant results were obtained about the role of 
depression on weight loss. Two studies27,28 pointed out no 
correlations between depression and weight loss; two found a 
negative association between depression and weight loss;24,45 
one35 showed depression as a positive predictor (r = 0.40, 
P , 0.05).
Demographic and anthropometric factors
Except for one study that pointed out a positive association 
between younger age and weight loss,35 age,27,45,46 and 
gender27,46 appeared to be unrelated to the ability to lose 
weight. According to the only study that considered the influ-
ence of race on weight loss,45 Caucasian ethnicity appeared 
a positive predictor (odds ratio [OR]: 0.42, P = 0.003). Two 
authors35,46 speculated that patients with higher pre-treatment 
body weight could achieve greater weight loss (r = 0.27, 
P , 0.001) because of their higher energy expenditure 
(resting metabolic rate) (r = 0.13, P = 0.003).46 Conversely, 
another study27 found no association between initial weight 
and weight loss at 6 months (r = −0.220, P = 0.242).
Familial obesity and personal  
weight history
One study27 pointed out the positive effect that the absence 
of familial obesity and having been normal weight at some 
points as an adult had on weight loss, even if these fac-
tors were not statistically selected as predictors (Student’s 
t-value = 3.239, P = 0.003; Student’s t-value = 2.194, 
P = 0.037 respectively). Conversely, Fabricatore et al45 
obtained better results treating patients with a longer history 
of overweight. Hansen et al46 showed the number of previous 
slimming attempts and the age of onset of obesity had no 
influence on final weight loss.
initial weight loss under treatment
Several studies24,27,29,45–48 showed that early adherence to the 
program, early weight loss in the lead-in period and in the first 
4 weeks of treatment were the strongest positive predictors of 
weight loss and maintenance, both in diabetic and nondiabetic 
patients. Accordingly, sibutramine prescribing guidelines49 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Table 4 Predictors of weight loss and maintenance in patients treated with sibutramine
Author, year Predictors
Psychosocial factors and eating behaviors elfhag et al27 PPwL: high deviating levels of demand states (hunger); high levels of 
dependency orientation and oral traits. Self-inspective ability  
ntPwL: levels of anxiety, depression, bodily concern; eating disorders;  
affective response to external stimuli
elfhag and  
Rossnerl19
PPwL: unrestrained eating (less cognitive control and conscious determination 
to resist from eating, less strategic dieting)  
ntPwL: hunger and disinhibition score; depressive features
elfhag et al35 PPwL: unrestrained eating (emotional and external eating); high levels of 
neuroticism, anxiety and depression. High levels of self-consciousness and hostility2
Fabricatore et al45 NPwL: depressive symptoms
Hainer et al24 NPwL: high dietary restraint at baseline; high initial depression score  
PPWL: increase in dietary restraint during first months of treatment PPWM: 
decrease in disinhibition scores
Demographic and anthropometric factors elfhag et al27 ntPwL: age; gender; pretreatment body weight
elfhag et al35 PPwL: young age
Fabricatore et al45 PPwL: Caucasian ethnicity ntPwL: age
Hansen et al46 PPwL: high baseline body weight (high resting metabolic rate)  
ntPwL: age; gender
Familial obesity and personal weight history elfhag et al27 NP: familial history of obesity; being obese during all adulthood
Fabricatore et al45 PPwL: having been overweight for a long time
Hansen et al46 ntPwL: age of obesity onset; number of previous slimming attempts
initial weight loss in the run in period  
and under treatment
elfhag et al27
Fabricatore et al45
Finer et al29
Hainer et al24
Hansen et al46
PPwL: great initial weight loss
PPwL: early adherence and weight loss
PPwL: high early weight loss ($4 kg at 3 months)
PPwL: high initial weight loss
PPwL: high initial weight loss in the run-in period; high initial weight  
loss under treatment  
ntPwL: number of previous slimming attempts; age of onset of obesity
van Baak et al48 
Grudell et al47
PPwM: high initial weight loss 
PPwL: high initial (4 weeks) weight loss
Genetic factors Frey et al50 PPwL: A allele carriers position −1211 of GNAS gene promoter
Grudell et al47 PPwL: gene pairs 5HTTLPR LS/SS and GNβ3 GNβ3 rs5443 TC/TT;  
α2A CC and GNβ3 rs5443 TC/TT
Hauner et al53 PPwL and PPwM: CC genotype of GNβ3 rs5443
Hsiao et al54 PPwL: T allele carriers (TT or TC genotype) of GNβ3 rs5443
Hsiao et al57 PPwL: −866 A polymorphism of UCP2; association between −866A 
polymorphism of UCP2 and rs5443 T polymorphism of GNβ3
Peters et al25 PPwL: homozygous A148A or G148G polymorphism of PNMT
vazquez  
Roque et al44
PPwL: LS/SS genotype of SLC6A4 ntPwL: α2A-1291 C/G;  
PNMT G148A polymorphism; GNβ3 genotypes
Associated pathologies, habits, nutritional,  
and environmental factors
Fabricatore et al45 PPwL: combined therapy (sibutramine + behavioral therapy)  
ntPwL: distance from clinic
Finer et al29 NPwL: diabetes
Greenway78 NPwL: diabetes
Hainer et al24 PPwM: increase in protein intake; decrease in fat intake  
ntPwM: 8 or 12 months of treatment
Hansen et al46 ntPwL: smoking history
LLoret- 
Linares et al37
NPwL: diabetes
Norris et al30 NPwL: diabetes
Peters et al25 ntPwL: postmenopausal state, hysterectomy, hormone replacement.  
Fiber intake, total caloric intake, total fat intake
Risser et al63 PPwL: priori authorization to have sibutramine as a prescription partially 
reimbursed (PAR)
Tankova et al59 NPwL: diabetes
van Baak et al48 PPwM: high levels of leisure-time physical activity  
ntPwM: macronutrient composition of the diet during weight maintenance period
Abbreviations: NPwL, negative predictor of weight loss; NPwM, negative predictor of weight maintenance; ntPwL, not predictor of weight loss; ntPwM, not predictor 
of weight maintenance; PPwL, positive predictor of weight loss; PPwM, positive predictor of weight maintenance.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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recommend physicians to increase the dose to 15 mg/day or 
discontinue treatment in patients who have not lost 2 kg in 
the first 4 weeks of treatment with the dose of 10 mg, and to 
avoid treatment beyond 12 weeks in people who fail to lose 
5% of their initial body weight.
Genetic factors
Some authors focused on the effect that several genetic 
  polymorphisms could have on weight loss and maintenance. 
Frey et al50 investigated the role of the G . A transition 
at position −1211 of the human G protein α-subunit gene 
(GNAS) promoter, showing that sibutramine was   effective 
only in A carriers (P = 0.002) (GG genotypes showed no 
additional weight loss under sibutramine compared to 
placebo). G   protein α-subunit is responsible for hormones 
coupling to the enzyme adenylyl-cyclase and is required 
in adipocytes for the lipolytic response to β adrenergic 
agonists.50
Four studies investigated GNB3, which encodes for the 
Gβ3 subunit of heteromeric G proteins (coupled to specific 
receptors, including serotonine and norepinephrine), key 
components of intracellular signal transduction, with a 
prominent role in body weight regulation. C825T (rs5443) 
polymorphism on exon 10 reduces lipolytic response to 
cathecolamines in fat cells51,52 and is associated with obe-
sity, hypertension, and diabetes. Hauner et al53 showed that 
sibutramine treatment was more effective in individuals with 
the CC genotype than in subjects with the TT/TC genotypes 
(weight loss: 7.2 ± 2.2 vs 4.1 ± 2.1 kg, P = 0.0013). In the 
CC group, the OR for a weight loss .5% (sibutramine vs 
placebo) was 6.6 (P = 0.004) and for a weight loss .10% 
was 9.6 (P = 0.010). This was in contrast with two studies47,54 
showing that patients with TT/TC genotypes achieved bet-
ter results than CC genotype (P = 0.018 and P , 0.001 
respectively), and another study44 pointing out no association 
between GNβ3 polymorphisms and weight loss.
One study25 focused on the positive association 
(P = 0.003) between weight loss and the homozygous variant 
(either G/G or A/A) G148A of PNMT (phenylethanolamine 
N-methyltransferase) encoding for an adrenal enzyme cata-
lyzing the conversion of norepinephrine to epinephrine55 but, 
in a second study, this result was not confirmed.44
Vazquez-Roque et al44 investigated also the role of “short” 
(S) and “long” (L) repeats in the 5-HTT-linked region of 
the promoter of gene SLC6A4 (solute carrier family 6, 
member 4; chromosome 17q11.1–q12) encoding for the 
soluble serotonin transporter56 and pointed out the positive 
effect of SLC6A4 LS/SS genotype on weight loss (subjects 
with SLC6A4 LS/SS genotype had an average weight loss 
of 6.1 ± 1.0 kg, compared with a 0.1 ± 0.9 kg average weight 
increase with placebo; subject with SLC6A4 LL genotype 
showed an average weight loss of 3.3 ± 1.8 kg on placebo, com-
pared with 3.9 ± 1.6 kg weight loss in sibutramine group).
Grudell et al47 found the positive effect of the association 
of TC/TT genotype of C825T polymorphism of GNβ3 gene 
and the CC genotype of α2A adrenoreceptor C1291G poly-
morphism or the 5HTTLPR LS/SS genotype.
Very recently, Hsiao et al57 used the same patients in which 
they had investigated the role of GNβ3 polymorphism54 to 
study the role of −866G/A polymorphism on weight loss in 
patients treated with sibutramine. The uncoupling protein 2 
(UCP2) gene encodes a mitochondrial transporter protein, 
which is highly expressed in adipose tissue, skeletal muscle, 
and pancreatic islets.58 A strong effect of sibutramine on 
weight loss was observed in individuals with the AA, GA, and 
AA + GA genotypes (P = 0.019, P , 0.001, and P , 0.001, 
respectively) whereas the drug caused no significant effect 
in individuals with the GG genotype (P = 0.063). For the 
combination of UCP2 AA + GA with GNβ3 TT + TC (car-
riers of at least one variant allele for each polymorphism), 
the P-value for treatment effects on weight loss was ,0.001. 
In contrast, no effects were observed in patients with the 
wild type genotype combination of UCP2 GG and GNβ3. 
A significant (P , 0.001) gene interaction between UCP2 
and GNβ3 was identified by a 2-locus model.
Associated pathologies, habits, nutritional, 
and environmental factors
Diabetes represents the chronic disease that most often is 
associated with obesity. Weight loss improves glycemic con-
trol and can be achieved using pharmacological therapy.30,37,59 
However in diabetic patients weight management is more 
challenging, in part because of the weight-promoting effects 
of the majority of anti-diabetic drugs37 and, on average, is 
achieved slower and less (up to 69%) than in nondiabetic 
patients.29,30,37,59 This final aspect is recognized by the 
Australian regulatory authorities who suggest to withdraw 
sibutramine after 3 months in nondiabetic patients who 
have failed to lose 5% of their initial body weight but after 
6 months in diabetic patients.60
On the other side, estrogen levels (ie, menopause, hor-
mone replacement), hysterectomy,25 and smoking habit46 
were demonstrated to not have a significant effect on weight 
loss in response to sibutramine.
The addition of behavioral therapy45 or high leisure-
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favorable effect on weight loss and maintenance, while 
dietetic modifications in fat, protein, and fiber intake24,25 
during the treatment, and the choice of 8 vs 12 months 
period of treatment24 did not have a great impact on 
outcomes. This is in accordance with most of studies on 
antiobesity drugs that demonstrate that the maximum 
weight loss is achieved after 6–8 months, whereas after 
12–16 months of treatment, minor weight regain usually 
occurs.61,62
A priori authorization to have sibutramine partially 
reimbursed improved patients’ compliance and weight loss.63 
Distance to the clinic was marginally related to treatment 
success.45
Predictors associated  
with mazindol treatments
Mazindol is a centrally acting drug that blocks the reuptake 
of norepinephrine by presynaptic neurons, increasing nor-
epinephrine levels within the synaptic cleft (Table 5). The 
result is the stimulation of the β2 adrenergic receptors in 
the lateral hypothalamus and the inhibition of feeding.11 It 
also inhibits gastric acid and insulin secretion, and increases 
locomotor activity.64
Psychosocial factors and eating behavior
A study in 197741 found that high social conformity and 
emotional stability, extraversion, and need for social accep-
tance improved patients’ adhesion to the program, whereas 
no personality characteristic predicted weight loss.
According to a more recent study,65 high levels of hunger, 
anxiety, and dietary restraint, and small perceived body size 
had a negative influence on weight loss in patients treated 
with mazindol. Suggested explanations for these findings 
were the drug incapability of controlling extreme levels of 
hunger, the limited slimming possibility in patients dieting 
before entering the treatment, and the individual lacking 
perception of the need for weight loss.
Genetic factors
Two studies66,67 pointed out a significantly greater body 
weight reduction in subjects with the Trp64 Trp allele than 
in those with Trp64Arg allele of ADRβ3 gene (encoding for 
a protein which regulates cathecolamine-induced lipolysis68 
mainly expressed in white adipose tissue) (6.9 ± 1.0 kg vs 
3.6 ± 0.7 kg in the first study and 8.4 ± 1.7 kg vs 3.7 ± 0.8 kg 
in the second study; P , 0.05).
Predictors associated with 
topiramate treatment
Topiramate is an anticonvulsant drug acting on sodium and 
calcium T-type channels (Table 6). The way in which it 
could promote weight loss is still unknown. Some authors 
have shown an increase in extraneuronal levels of dopamine, 
norepinephrine, and serotonin in the hippocampus and have 
speculated that a similar effect in the hypopthalamus could 
explain topiramate action as an appetite suppressor.69 Other 
studies have demonstrated an increase in fat metabolism 
(through the increased activity of lipoprotein lipase in adipose 
tissue and promotion of hepatic fat metabolism and decreased 
fatty acid synthesis)70,71 and the inhibition of lipogenesis 
through the inhibition of carbonic anhydrase II and V .72
A recent meta-analysis9 based on studies conducted on epi-
leptic patients reported an average placebo-subtracted weight 
loss of 6.5% in topiramate-treated patients (P , 0.001). 
Adverse effects are paresthesia, changes in taste, dizziness, 
memory impairment, insomnia, and somnolence.9,73
Demographic and anthropometric factors
Three studies74–76 pointed out a correlation between higher 
initial BMI and a greater weight loss (P , 0.001) in epileptic 
patients treated with topiramate for a period of 10 weeks to 
6 months. Only one study77 conducted on migraine patients 
treated for 4 months found no correlation between initial 
BMI, gender, and total weight loss (P = 0.44).
Table 5 Predictors of weight loss and maintenance in patients treated with mazindol
Author, year Predictors
Psychosocial factors and  
eating behaviors
Rodin et al41 PPwL: high levels of social conformity; belief that poor eating habits are crucial in producing obesity   
NPwL: high levels of responsiveness to external, non-food relevant stimuli; belief that hereditary 
or physical factors are causes of primary importance in producing overweight  
ntPwL: self-esteem and self-concept; emotional stability; extraversion; internal locus of control.
womble et al65 NPwL: high levels of dietary restraint, perceived hunger and trait anxiety; small perceived body size
Genetic predictors Shimizu and  
Mori66  
Shimizu et al67
NPwL: Trp64Arg mutation of GNβ3 gene (vs Trp64Trp)
Abbreviations: NPwL, negative predictor of weight loss; NPwM, negative predictor of weight maintenance; ntPwL, not predictor of weight loss; ntPwM, not predictor 
of weight maintenance; PPwL, positive predictor of weight loss; PPwM, positive predictor of weight maintenance.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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eating behavior
One study76 reported a positive (P = 0.002) association 
between a reduction in hunger after 3 months of treatment 
and total weight loss at month 6.
Results
Our analysis pointed out the overall paucity of reliable 
predictors of weight loss and maintenance associated with 
pharmacological antiobesity treatments, a characteristic 
previously described by studies focusing on lifestyle modi-
fication treatments.18,19
Indeed, among all considered factors, the early 
response to treatment was demonstrated to be a sure posi-
tive predictor of weight loss and maintenance. Conversely, 
diabetes appeared to have a strong negative impact on 
patients’ ability to lose weight when treated with the dif-
ferent drugs.
A more unrestrained eating at baseline and high levels 
of determination and self-discipline appeared to be positive 
predictors of outcome in patients treated with sibutramine 
and orlistat, respectively, even if the statistical association 
was less strong.
For all other considered variables, published data are not 
sufficient to define their role on final outcomes.
Conclusion
Limitations related both to the disease and to the inter-
vention program could explain these inconclusive and 
often conflicting results. Indeed, the multitude of factors 
involved in obesity’s development and weight loss, and 
their complex interactions make each patient different 
from the other and the investigation of reliable predictors 
particularly challenging. Furthermore psycho-behavioral 
difficulties experienced by patients when starting a new 
treatment, and the lack of significant results often associ-
ated with the different therapies, are responsible for the 
high levels of attrition of patients from the weight-loss 
programs.
At the same time, our analysis pointed out important limi-
tations related to currently available literature investigating 
outcomes associated to antiobesity pharmacological 
  treatments. First of all, few studies have been conducted 
with the primary aim to point out the role of specific factors 
on weight loss and maintenance. Second, a minor part of 
these studies have included a large cohort of patients. Third, 
studies are very heterogeneous from the point of view of the 
number and characteristics of patients included, the duration 
and type of program, and the tests and parameters used for 
patients’ evaluation. Finally, very often, the analysis and 
interpretation of the achieved results are very difficult and the 
power of the associations is reduced because of the limited 
number of subjects included.
Probably, the enrollment of a greater number of patients 
in future trials, the use of common protocols of treatment and 
parameters (for each category of predictors) to assess final 
outcomes could improve statistical significance of results and 
the ability to compare data. Moreover, because both obesity 
onset and weight loss are dependent on the interaction of a 
great number of different factors, it could be important to 
test different categories of predictors on the same group of 
patients.
Despite the above mentioned difficulties and the dis-
couraging results obtained until recently, we believe that, 
because of obesity’s social and medical impact and the 
  availability of new promising antiobesity drugs (whose 
  mechanisms of action are very often similar to those of 
old drugs; the most promising one is the association of 
  bupropion and naltrexone),79 the search for reliable predictors 
of o  utcome associated to antiobesity treatments has to be 
supported and encouraged.
Being able to find reliable predictors of successful out-
come for pharmacological treatments would mean to give 
prescribing physicians, patients, and the authorities a tool 
for antiobesity drug management.
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